Accordingly, even after controlling for variables such as tumor stage, tumor size, positive lymph nodes, and obesity, HR−/HER2+ patients still had a lower cure probability in the long time. This evidence concerns the gene ERBB2 and obesity due to melanocortin 4 receptor deficiency.